Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Shifts Gears In China With New Shanghai-based R&D Center

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes

You may also be interested in...



An Asia Hub: Novartis Plans Biotech Manufacturing Center In Singapore

Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.

Lilly Diabetes R&D Center Arms Firm For Battle In China

Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.

New Diabetes R&D Center Arms Eli Lilly For Battle In China

Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.

Related Content

UsernamePublicRestriction

Register

SC073694

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel